石杉碱甲联合尼莫地平治疗轻中度血管性痴呆的疗效观察  

Observation of huperzine A conbined with nimodipine in the treatment of vascular dementia

作　　者：徐猛 

机构地区：[1]河南杞县中医院神经内科,杞县475200

出　　处：《中国实用神经疾病杂志》2012年第20期15-17,共3页Chinese Journal of Practical Nervous Diseases

摘　　要：目的观察石杉碱甲联合尼莫地平治疗轻中度血管性痴呆的疗效及安全性。方法 80例血管性痴呆患者随机分为治疗组40例和对照组40例,在常规治疗基础上,对照组口服尼莫地平+吡拉西坦;治疗组口服尼莫地平+石杉碱甲。2组均治疗6个月。检测2组患者治疗前后MMSE、ADL、HDS-R评分及药物不良反应。结果治疗6个月后,2组患者的MMSE、ADL、HDS-R评分比治疗前均明显升高,差异有统计学意义(P<0.01或P<0.05);而治疗组MMSE、ADL、HDS-R评分改善更显著(P<0.01)。2组均未发生严重不良反应。结论石杉碱甲联合尼莫地平治疗轻中度血管性痴呆疗效显著优于吡拉西坦联合尼莫地平,安全性相同。Objective To observe the curative effect and safety of huperzine A conbined with nimodipine in the treatment of vascular dementia. Methods Totally 80 cases of vascular dementia were randomly divided into two groups, treatment group （40 cases） and control group （40 cases）. On the base of conventional therapy, control group was treated with nimodipine andpiracetam treatment; treatment group was treated with nimodipine and Huperzine A. All the patients were treated for 6 months. MMSE, ADL, HDS-R scores and adverse drug reaction in two groups were detected before and after treat- ment. Results After 6 months of treatment, MMSE, ADL, HDS-R scores in two groups were significantly higher than that before trcatment（P〈0.01 or P〈0.05） ; MMSE, ADL, HDS-R scores in treatment group improved more significantly than that in control group（P〈0.01）. Patients in the two groups had no serious adverse reactions. Conclusion Huperzine A con- bined with nimodipine is significantly superior to piracetam conbined with nimodipine in the treatment of mild to moderate vas- cular dementia, but they have same security.

关 键 词：石杉碱甲 尼莫地平 吡拉西坦 血管性痴呆 

分 类 号：R749.13[医药卫生—神经病学与精神病学]